Tag: tucatinib

HER2-positive breast cancer targeted therapies trastuzumab T-DXd T-DM1 tucatinib HER2-low

HER2-Positive Breast Cancer: Targeted Therapies Explained

HER2-positive breast cancer, once aggressive and hard to treat, is now highly manageable thanks to targeted therapies like trastuzumab, T-DXd, and tucatinib. Learn how these drugs work, their side effects, and the latest advances changing survival rates.

December 21 2025